Tendon rupture as an adverse effect of rasagiline.
Identifieur interne : 000600 ( PubMed/Corpus ); précédent : 000599; suivant : 000601Tendon rupture as an adverse effect of rasagiline.
Auteurs : Romain Lefaucheur ; Damien Fetter ; Gaëlle Gaillon ; Alaina Borden ; David MaltêteSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Indans, Monoamine Oxidase Inhibitors.
- chemically induced : Rupture, Spontaneous, Tendon Injuries.
- Aged, Female, Humans.
Abstract
A 66-year-old woman with advanced Parkinson disease (PD) was referred to our center for an adjustment of her antiparkinsonian medication. To reduce daily off-time, we introduced rasagiline 1 mg/d. Three days after starting this new treatment, she presented with intense arthralgia that symmetrically affected the shoulders, hands, and hips without myalgia. Ten days later, while walking, she experienced acute pain on the inner side of her right thigh, with the absence of any trauma. Findings of ultrasonography confirming the diagnosis of partial avulsion of the right harmstrings. Rasagiline was stopped immediately, and the arthralgia disappeared within 48 hours and did not recur. To our knowledge, this is the first reported case of a spontaneous tendon rupture possibly caused by rasagiline. Our observation emphasizes that, although often well tolerated, rasagiline may cause muscle and joint complications that could increase disability in patients with PD.
DOI: 10.1097/WNF.0000000000000023
PubMed: 24614673
Links to Exploration step
pubmed:24614673Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tendon rupture as an adverse effect of rasagiline.</title><author><name sortKey="Lefaucheur, Romain" sort="Lefaucheur, Romain" uniqKey="Lefaucheur R" first="Romain" last="Lefaucheur">Romain Lefaucheur</name><affiliation><nlm:affiliation>Departments of *Neurology, †Pharmacology, Rouen University Hospital, University of Rouen, and ‡Faculty of Medicine, University of Rouen, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fetter, Damien" sort="Fetter, Damien" uniqKey="Fetter D" first="Damien" last="Fetter">Damien Fetter</name></author><author><name sortKey="Gaillon, Gaelle" sort="Gaillon, Gaelle" uniqKey="Gaillon G" first="Gaëlle" last="Gaillon">Gaëlle Gaillon</name></author><author><name sortKey="Borden, Alaina" sort="Borden, Alaina" uniqKey="Borden A" first="Alaina" last="Borden">Alaina Borden</name></author><author><name sortKey="Maltete, David" sort="Maltete, David" uniqKey="Maltete D" first="David" last="Maltête">David Maltête</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2014 Mar-Apr</MedlineDate></PubDate></date><idno type="RBID">pubmed:24614673</idno><idno type="pmid">24614673</idno><idno type="doi">10.1097/WNF.0000000000000023</idno><idno type="wicri:Area/PubMed/Corpus">000600</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000600</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tendon rupture as an adverse effect of rasagiline.</title><author><name sortKey="Lefaucheur, Romain" sort="Lefaucheur, Romain" uniqKey="Lefaucheur R" first="Romain" last="Lefaucheur">Romain Lefaucheur</name><affiliation><nlm:affiliation>Departments of *Neurology, †Pharmacology, Rouen University Hospital, University of Rouen, and ‡Faculty of Medicine, University of Rouen, Rouen, France.</nlm:affiliation></affiliation></author><author><name sortKey="Fetter, Damien" sort="Fetter, Damien" uniqKey="Fetter D" first="Damien" last="Fetter">Damien Fetter</name></author><author><name sortKey="Gaillon, Gaelle" sort="Gaillon, Gaelle" uniqKey="Gaillon G" first="Gaëlle" last="Gaillon">Gaëlle Gaillon</name></author><author><name sortKey="Borden, Alaina" sort="Borden, Alaina" uniqKey="Borden A" first="Alaina" last="Borden">Alaina Borden</name></author><author><name sortKey="Maltete, David" sort="Maltete, David" uniqKey="Maltete D" first="David" last="Maltête">David Maltête</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="eISSN">1537-162X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Indans (adverse effects)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Rupture, Spontaneous (chemically induced)</term><term>Tendon Injuries (chemically induced)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Rupture, Spontaneous</term><term>Tendon Injuries</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 66-year-old woman with advanced Parkinson disease (PD) was referred to our center for an adjustment of her antiparkinsonian medication. To reduce daily off-time, we introduced rasagiline 1 mg/d. Three days after starting this new treatment, she presented with intense arthralgia that symmetrically affected the shoulders, hands, and hips without myalgia. Ten days later, while walking, she experienced acute pain on the inner side of her right thigh, with the absence of any trauma. Findings of ultrasonography confirming the diagnosis of partial avulsion of the right harmstrings. Rasagiline was stopped immediately, and the arthralgia disappeared within 48 hours and did not recur. To our knowledge, this is the first reported case of a spontaneous tendon rupture possibly caused by rasagiline. Our observation emphasizes that, although often well tolerated, rasagiline may cause muscle and joint complications that could increase disability in patients with PD.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24614673</PMID><DateCreated><Year>2014</Year><Month>03</Month><Day>17</Day></DateCreated><DateCompleted><Year>2015</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>2</Issue><PubDate><MedlineDate>2014 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Tendon rupture as an adverse effect of rasagiline.</ArticleTitle><Pagination><MedlinePgn>62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WNF.0000000000000023</ELocationID><Abstract><AbstractText>A 66-year-old woman with advanced Parkinson disease (PD) was referred to our center for an adjustment of her antiparkinsonian medication. To reduce daily off-time, we introduced rasagiline 1 mg/d. Three days after starting this new treatment, she presented with intense arthralgia that symmetrically affected the shoulders, hands, and hips without myalgia. Ten days later, while walking, she experienced acute pain on the inner side of her right thigh, with the absence of any trauma. Findings of ultrasonography confirming the diagnosis of partial avulsion of the right harmstrings. Rasagiline was stopped immediately, and the arthralgia disappeared within 48 hours and did not recur. To our knowledge, this is the first reported case of a spontaneous tendon rupture possibly caused by rasagiline. Our observation emphasizes that, although often well tolerated, rasagiline may cause muscle and joint complications that could increase disability in patients with PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lefaucheur</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of *Neurology, †Pharmacology, Rouen University Hospital, University of Rouen, and ‡Faculty of Medicine, University of Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fetter</LastName><ForeName>Damien</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gaillon</LastName><ForeName>Gaëlle</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Borden</LastName><ForeName>Alaina</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Maltête</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007189">Indans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>003N66TS6T</RegistryNumber><NameOfSubstance UI="C031967">rasagiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012422" MajorTopicYN="N">Rupture, Spontaneous</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013708" MajorTopicYN="N">Tendon Injuries</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24614673</ArticleId><ArticleId IdType="doi">10.1097/WNF.0000000000000023</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000600 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000600 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24614673
|texte= Tendon rupture as an adverse effect of rasagiline.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24614673" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |